The clinical study of the safety and efficacy of docetaxel combined with ribavirin in docetaxel resistant castration resistant prostate cancer

The clinical study of the safety and efficacy of docetaxel combined with ribavirin in docetaxel resistant castration resistant prostate cancer - The clinical study of the safety and efficacy of docetaxel combined with ribavirin in docetaxel resistant castration resistant prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015130

Enrollment

Registered

2014-09-12

Start date

2013-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Ribavirin

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Adenocarcinoma of the prostate histologically confirmed Progressive Prostate cancer based on PSA and/or radiographic criteria. Stable medical condition, including the absence of severe hepatological, cardiac renal and hematological disorder etc

Exclusion criteria

Exclusion criteria: Uncontroled general complication. Diagnosis of or treatment for another systemic malignancy. etc

Design outcomes

Primary

Measure	Time frame
PSA response rate rPFS safety	—

Countries

Japan

Contacts

Public ContactTakeo Kosaka

Keio University School of Medicine Department of Urology

takemduro@a6.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026